For decades, Alzheimer's disease was diagnosed primarily through cognitive decline — meaning intervention came only after substantial neurodegeneration had already occurred. A new analytical framework now maps how fluid biomarkers are closing that gap, enabling biological detection of Alzheimer's pathology years before a single symptom emerges, and potentially reducing dependence on costly PET imaging.
The review, published in the International Journal of Molecular Sciences, traces the biomarker pipeline from initial discovery to regulatory-approved clinical tools. Mass spectrometry-based proteomics anchors the discovery phase, allowing unbiased identification of novel candidates across diverse biological pathways beyond the classical amyloid-β and tau signatures. Validation advances through immunoassay platforms — including ELISA, electrochemiluminescence immunoassays, and microfluidic systems — culminating in ultrasensitive single-molecule array (SIMOA) technology capable of detecting proteins at subfemtomolar concentrations in blood. The translation endpoint is represented by fully automated platforms, Lumipulse and Elecsys, which have received regulatory clearance for both cerebrospinal fluid and, critically, blood-based biomarkers — a meaningful shift toward scalable, minimally invasive screening.
The significance here is not any single biomarker discovery but the maturing infrastructure connecting research findings to clinical deployment. Blood-based phosphorylated tau variants (particularly p-tau217) have shown strong discriminatory performance in recent head-to-head validation studies, suggesting the field is approaching a genuinely usable pre-symptomatic screening window. However, substantial obstacles persist: inter-platform variability means a result on one system cannot be reliably compared to another, reference standardization remains incomplete, and real-world diagnostic accuracy outside highly characterized research cohorts is still being established. The review underscores that regulatory approval for a platform does not automatically resolve these operational challenges. For longevity-focused adults, the trajectory is encouraging — blood tests for Alzheimer's risk stratification appear closer to routine clinical integration than at any prior point — but population-wide implementation requires standardization infrastructure that does not yet fully exist.